Evidence map›Paper›PMID 26928668›Full record

ArticlePharmaceutical research2016

Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Sharon S Y Leung, Thaigarajan Parumasivam, Fiona G Gao, Nicholas B Carrigy, Reinhard Vehring, Warren H Finlay, Sandra Morales, Warwick J Britton, Elizabeth Kutter, Hak-Kim Chan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 146 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. EudragitPharmaceutics · 2023
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Sharon S Y LeungFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Thaigarajan ParumasivamFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Fiona G GaoFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia.
Nicholas B CarrigyDepartment of Mechanical Engineering, University of Alberta, Edmonton, Alberta, T6G 2G8, Canada.
Reinhard VehringDepartment of Mechanical Engineering, University of Alberta, Edmonton, Alberta, T6G 2G8, Canada.
Warren H FinlayDepartment of Mechanical Engineering, University of Alberta, Edmonton, Alberta, T6G 2G8, Canada.
Sandra MoralesAmpliPhi Biosciences AU, 7/27 Dale Street, Brookvale, Sydney, NSW, 2100, Australia.
Warwick J BrittonTuberculosis Research Program, Centenary Institute and Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
Elizabeth KutterThe Evergreen State College, Olympia, Washington, 98502, USA.
Hak-Kim ChanFaculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia. kim.chan@sydney.edu.au.
University of Sydney · AUUniversity of Alberta · CAAgriBio · AUThe Evergreen State College · US

Funding

Harnessing bacteriophages as natural predators to combat the superbugs: a pulmonary drug delivery approachR21AI121627 · NIAID · UNIVERSITY OF SYDNEY · PI CHAN, KIM · 2016 to 2017
$287k
NIAID NIH HHS R21 AI121627
6 · The paper itself

Abstract

purposeThe potential of aerosol phage therapy for treating lung infections has been demonstrated in animal models and clinical studies. This work compared the performance of two dry powder formation techniques, spray freeze drying (SFD) and spray drying (SD), in producing inhalable phage powders.

methodA Pseudomonas podoviridae phage, PEV2, was incorporated into multi-component formulation systems consisting of trehalose, mannitol and L-leucine (F1 = 60:20:20 and F2 = 40:40:20). The phage titer loss after the SFD and SD processes and in vitro aerosol performance of the produced powders were assessed.

resultsA significant titer loss (~2 log) was noted for droplet generation using an ultrasonic nozzle employed in the SFD method, but the conventional two-fluid nozzle used in the SD method was less destructive for the phage (~0.75 log loss). The phage were more vulnerable during the evaporative drying process (~0.75 log further loss) compared with the freeze drying step, which caused negligible phage loss. In vitro aerosol performance showed that the SFD powders (~80% phage recovery) provided better phage protection than the SD powders (~20% phage recovery) during the aerosolization process. Despite this, higher total lung doses were obtained for the SD formulations (SD-F1 = 13.1 ± 1.7 × 10(4) pfu and SD-F2 = 11.0 ± 1.4 × 10(4) pfu) than from their counterpart SFD formulations (SFD-F1 = 8.3 ± 1.8 × 10(4) pfu and SFD-F2 = 2.1 ± 0.3 × 10(4) pfu).

conclusionOverall, the SD method caused less phage reduction during the powder formation process and the resulted powders achieved better aerosol performance for PEV2.

Indexed as

Administration, InhalationAerosolsFreeze DryingLeucineLungMannitolMicrobial ViabilityNebulizers and VaporizersPhage TherapyPodoviridaePowdersPseudomonasPseudomonas InfectionsRespiratory Tract InfectionsTrehaloseUltrasonicsAerosolsLeucineMannitolPowdersTrehaloseaerosolsantibiotic-resistant bacteriaphage therapypulmonary infections

Identifiers

PMID26928668
PMCPMC5083036
OpenAlexW2289356514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.